tetano
Editor, Senior Moderator
Korean J Intern Med
. 2022 Aug 22.
doi: 10.3904/kjim.2022.072. Online ahead of print.
Clinical characteristics of patients with COVID-19 vaccine-related pneumonitis: a case series and literature review
Ji Young Park[SUP] 1 [/SUP], Joo-Hee Kim[SUP] 1 [/SUP], Sunghoon Park[SUP] 1 [/SUP], Yong Il Hwang[SUP] 1 [/SUP], Hwan Il Kim[SUP] 1 [/SUP], Seung Hun Jang[SUP] 1 [/SUP], Ki-Suck Jung[SUP] 1 [/SUP], Yong Kyun Kim[SUP] 2 [/SUP], Hyun Ah Kim[SUP] 3 [/SUP], In Jae Lee[SUP] 4 [/SUP]
Affiliations
Abstract
Background/aims: Pulmonary toxicities of coronavirus disease 2019 (COVID-19) vaccination are exceedingly rare. However, there are a few reported cases after mRNA vaccination, especially from Asian countries. The purpose of this study was to report the clinical characteristics of patients with COVID-19 vaccine-related pneumonitis (CV-P) and to review cases reported in the literature.
Methods: We performed a prospective, observational case series analysis.
Results: Eleven patients with a median age of 80 years were enrolled. Ten patients developed CV-P after BNT162b2-mRNA vaccination and one after ChAdOx1 nCoV-19 vaccination. We identified various patterns of CV-P, including transient infiltration, life-threatening acute respiratory distress syndrome, and aggravation of underlying interstitial lung disease. Most patients showed favorable outcomes with good responses to corticosteroid therapy.
Conclusions: Identifying the mechanism of CV-P requires further investigation; however, radiological and laboratory findings in our case series support inflammatory dysregulation in the lung parenchyma after vaccination. Clinicians should consider CV-P in patients with atypical lung infiltration, no specific etiologies, and recent COVID-19 vaccination.
Keywords: COVID-19; Drug-related side effects and adverse reactions; Lung diseases, interstitia; Pneumonitis; Vaccines.
. 2022 Aug 22.
doi: 10.3904/kjim.2022.072. Online ahead of print.
Clinical characteristics of patients with COVID-19 vaccine-related pneumonitis: a case series and literature review
Ji Young Park[SUP] 1 [/SUP], Joo-Hee Kim[SUP] 1 [/SUP], Sunghoon Park[SUP] 1 [/SUP], Yong Il Hwang[SUP] 1 [/SUP], Hwan Il Kim[SUP] 1 [/SUP], Seung Hun Jang[SUP] 1 [/SUP], Ki-Suck Jung[SUP] 1 [/SUP], Yong Kyun Kim[SUP] 2 [/SUP], Hyun Ah Kim[SUP] 3 [/SUP], In Jae Lee[SUP] 4 [/SUP]
Affiliations
- PMID: 35989064
- DOI: 10.3904/kjim.2022.072
Abstract
Background/aims: Pulmonary toxicities of coronavirus disease 2019 (COVID-19) vaccination are exceedingly rare. However, there are a few reported cases after mRNA vaccination, especially from Asian countries. The purpose of this study was to report the clinical characteristics of patients with COVID-19 vaccine-related pneumonitis (CV-P) and to review cases reported in the literature.
Methods: We performed a prospective, observational case series analysis.
Results: Eleven patients with a median age of 80 years were enrolled. Ten patients developed CV-P after BNT162b2-mRNA vaccination and one after ChAdOx1 nCoV-19 vaccination. We identified various patterns of CV-P, including transient infiltration, life-threatening acute respiratory distress syndrome, and aggravation of underlying interstitial lung disease. Most patients showed favorable outcomes with good responses to corticosteroid therapy.
Conclusions: Identifying the mechanism of CV-P requires further investigation; however, radiological and laboratory findings in our case series support inflammatory dysregulation in the lung parenchyma after vaccination. Clinicians should consider CV-P in patients with atypical lung infiltration, no specific etiologies, and recent COVID-19 vaccination.
Keywords: COVID-19; Drug-related side effects and adverse reactions; Lung diseases, interstitia; Pneumonitis; Vaccines.